Quantcast

Latest Biomarker Stories

2014-05-27 08:28:53

WALTHAM, Mass., May 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 - June 3, 2014, in Chicago. The first poster, titled "Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer," is being...

2014-05-23 20:21:52

GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen's Vectibix(R) (panitumumab) in treatment of metastatic colorectal cancer - FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN's leadership in molecular companion diagnostics for personalized healthcare - QIAGEN driving the adoption of molecular tests...

2014-05-23 08:23:59

SHANGHAI, May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced a strategic biomarker collaboration. Through this collaboration, Targos will provide know-how, services, and the quality standards to support WuXi's bioanalytical work for pharmaceutical customers. The...

2014-05-21 16:27:24

CASTLE ROCK, Colo., May 21, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will participate in the 11(th) Annual Craig-Hallum Institutional Investor Conference, to be held May 28, 2014, at the Minneapolis Marriott City Center. Steve Lundy,...

2014-05-21 08:29:37

MOUNTAIN VIEW, Calif., May 21, 2014 /PRNewswire-USNewswire/ -- The Open Medicine Institute (OMI), an organization with a mission to improve health care by applying a multi-disciplinary, "big data" approach, today announced that it will begin development of a biomarker for Chronic Fatigue Syndrome (CFS) and other prevalent, chronic but difficult-to-diagnose diseases. Plans are in place for development of two key tests - a detection biomarker based on RNA expression data from patients...

2014-05-20 23:07:09

A funding round of $2 million will help biotech firm carry out clinical trials and commercialization of early breast cancer detection test. Fayetteville, Arkansas and Vancouver, Washington (PRWEB) May 20, 2014 The average non-high risk American woman will undergo at least one, if not more, biopsies to evaluate a suspicious mass within her lifetime. Women within the high-risk population will undergo multiple biopsies as well as endure more frequent follow up breast imaging tests. The costs...

2014-05-19 23:05:25

According to a new report from BCC Research, the global market for biomarkers is expected to grow to $53.6 billion by 2018, with a five-year compound annual growth rate (CAGR) of 12.8%. The bioinformatics category, the fastest moving segment overall, is expected to move at a significant 17.4% CAGR. Wellesley, Mass., (PRWEB) May 19, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS, the global market for biomarkers is...

2014-05-19 12:27:37

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cancer Profiling and Pathways: Technologies and Global Marketshttp://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.htmlSTUDY GOALS AND OBJECTIVESThis BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and...

2014-05-14 23:16:42

Three key new patents are issued to Aushon for its Multiplex Platform. Billerica, MA (PRWEB) May 14, 2014 Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced that it has continued to build its patent portfolio with the issuance of three new patents. Two of the patents relate to technology innovations utilized in the fabrication of multiplex protein panels commercialized as part of Aushon’s Cira™...

2014-05-12 08:31:04

IRVING, Texas, May 12, 2014 /PRNewswire/ -- North Shore Hematology Oncology Associates (NSHOA) and Caris Life Sciences today announced a collaboration to establish a personalized cancer care program for patients in the greater Long Island area. This program will leverage the power of Caris Molecular Intelligence(TM), the industry's leading comprehensive tumor profiling service, to better target therapy options based on each patient's unique cancer biology. With the addition of this...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related